1-4 of 4
Jaime Feliu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

Francesca Sarno, Jair Tenorio, Sofia Perea, Laura Medina, Roberto Pazo-Cid, Ignacio Juez, Rocío Garcia-Carbonero, Jaime Feliu, Carmen Guillen-Ponce, Pedro P. Lopez-Casas, Carmen Guerra, Yolanda Duran, José Francisco López-Acosta, Carolina Alonso, Estrella Esquivel, Ana Dopazo, Dipikaa Akshinthala, Senthil K. Muthuswamy, Pablo Lapunzina, Bruno Bockorny, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 278–287.
https://doi.org/10.1158/1078-0432.CCR-23-4026
Published: 17 January 2025
View article titled, A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
Open the PDF for A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial in another window
Includes: Supplementary data
Journal Articles

An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.

Caiming Xu, Alessandro Mannucci, Francis Esposito, Helena Oliveres, Vicente Alonso Orduña, Alfonso Yubero, Carlos Fernández-Martos, Antonieta Salud, Javier Gallego, Marta Martin-Richard, Julen Fernández-Plana, Monica Guillot, Jorge Aparicio, Marwan Fakih, Scott Kopetz, Jaime Feliu, Joan Maurel, Ajay Goel
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-1934
Published: 17 January 2025
View article titled, An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
Open the PDF for An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study. in another window
Includes: Supplementary data
Journal Articles

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, Erkut Borazanci, Jaime Feliu, Mariano Ponz-Sarvise, David Gutierrez Abad, Paul Oberstein, Angela Alistar, Andres Muñoz, Ravit Geva, Carmen Guillén-Ponce, Mercedes Salgado Fernandez, Amnon Peled, Marya Chaney, Irit Gliko-Kabir, Liron Shemesh-Darvish, Debby Ickowicz, Ella Sorani, Shaul Kadosh, Abi Vainstein-Haras, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5020–5027.
https://doi.org/10.1158/1078-0432.CCR-21-0929
Published: 15 September 2021
View article titled, Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Open the PDF for Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial in another window
Includes: Supplementary data
Journal Articles

A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer

Enrique Casado, Victor Moreno García, Jose Javier Sánchez, Montserrat Blanco, Joan Maurel, Jaime Feliu, Carlos Fernández-Martos, Javier de Castro, Beatriz Castelo, Cristóbal Belda-Iniesta, María Sereno, Benito Sánchez-Llamas, Emilio Burgos, Miguel Ángel García-Cabezas, Noemí Manceñido, Rosa Miquel, Damián García-Olmo, Manuel González-Barón, Paloma Cejas
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4145–4154.
https://doi.org/10.1158/1078-0432.CCR-10-2257
Published: 15 June 2011
View article titled, A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer
Open the PDF for A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer in another window
Includes: Supplementary data